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  Muscle	  wasting	  during	   critical	   illness	   has	  been	   suggested	   to	   contribute	   to	   survivor	  
functional	  disability(1).	  Two	  B-­‐mode	  ultrasound	  measures	  measurements	  have	  been	  
reported	   that	  quantify	  wasting(2,	   3):	   (i)	   combined	   thickness	  of	   the	  Rectus	   Femoris	  
(RF)	  and	  Vastus	  Intermedius	  muscles	  (‘Muscle	  Layer	  Thickness’,	  henceforth	  referred	  
to	  as	  ‘Thickness’)	  (4,	  5)	  and	  (ii)	  RF	  cross-­‐sectional	  area	  (RFCSA)	  which	  correlates	  with	  
lower	  limb	  strength	  in	  other	  clinical	  circumstances	  (6).	  The	  degree	  to	  which	  either	  of	  
these	  ultrasound	  measures	  reflect	  muscle	  weakness	  in	  the	  critically	  ill	  is	  unclear	  (7).	  	  
We	  hypothesised	  that	  like	  change	  in	  RFCSA	  (ΔRFCSA),	  change	  in	  Thickness	  (ΔThickness)	  
would	   underestimate	   loss	   of	   muscle	   size	   as	   measured	   by	   the	   histological	   gold	  
standard	  	  (myofibre	  thickness)	  and	  the	  biochemical	  gold	  standard	  	  	  of	  protein:	  DNA	  
ratio	  measured	   in	   skeletal	  muscle	   biopsies.	   Secondly	  we	   hypothesised	   that	   ΔRFCSA	  
and	  ΔThickness	  would	  both	  be	  related	  to	  muscle	  weakness.	  
Subjects	   were	   patients	   of	   the	   Musculoskeletal	   Ultrasound	   in	   Critical	   Illness:	  
Longitudinal	   Evaluation	   study	   (NCT01106300)	   (8),	   the	   original	   study	   having	   been	  
approved	   by	   University	   College	   London	   Ethics	   Committee	   A.	   All	   patients	   were	  
recruited	   within	   24	   hours	   of	   admission	   to	   a	   university	   hospital	   and	   a	   community	  
hospital	  (August	  2009-­‐April	  2011),	  and	  were	  expected	  to	  survive	  intensive	  care	  unit	  	  
(ICU)	   admission	   after	   being	   invasively	   ventilated	   for	   >	   48	   hours	   and	   in	   the	   ICU	   >7	  
days.	   Excluded	   were	   those	   with	   pregnancy,	   lower	   limb	   amputation,	   primary	  
neuromuscular	   pathology	   or	   disseminated	   cancer.	   	   Next-­‐of-­‐kin	   assent	   and	  
retrospective	  patient	  consent	  were	  obtained.	  
Images	  were	  acquired	  on	  ICU	  days	  1,	  7	  and	  10.	  ICU	  RFCSA	  assessment	  and	  reliability	  
have	   been	   previously	   described	   (8).	   Thickness	   was	   measured	   at	   the	   midpoint	   of	  
Rectus	   Femoris	   between	   the	   two	   fascial	   lines.	   Images	   were	   excluded	   where	   the	  
femur	  was	  not	  visible.	  
ΔThickness	  and	  ΔRFCSA	  were	  compared	  with	  change	  In	  myofibre	  cross-­‐sectional	  area	  
(ΔfibreCSA)	  and	  protein:DNA	   in	   sequential	  Vastus	  Lateralis	  muscle	  biopsies	  acquired	  
on	  days	  1	  and	  7	  as	  described	  previously	  (8).	  
Manual	  Muscle	  Testing	  was	  performed	  (9)	  on	  day	  10	  if	  patients	  could	  follow	  >3	  of	  De	  
Jonghe’s	  5-­‐command	  criteria	  and	  the	  knee	  extension	  component	  score	  of	  <4/5	  	  used	  
to	  define	  lower	  limb	  weakness	  (10).	  	  	  
Bland-­‐Altman	   comparisons	   were	   used	   to	   establish	   i)	   inter-­‐rater	   reliability	   of	  
Thickness	   measurements	   and	   ii)	   longitudinal	   bias	   between	   ΔThickness	   and	   ΔRFCSA	  
over	   the	   study	   period.	   Normality	   was	   assessed	   using	   D’Agostino	   and	   Pearson	  
omnibus	  normality	  tests,	  and	  data	  were	  analysed	  using	  two-­‐tailed	  Student’s	  t-­‐test	  or	  
Mann	  Whitney	  U	  test	  as	  appropriate.	  Differential	  longitudinal	  change	  in	  muscle	  size	  
(ΔThickness	   vs.	   ΔRFCSA)	  was	   compared	  using	   2-­‐way	   repeated	  measures	   of	   variance	  
(ANOVA).	   A	   bivariable	   logistical	   regression	   was	   performed	   with	   knee	   extensor	  
weakness	   as	   the	   dependent	   variable	   and	   ultrasound	   measurements	   as	   the	  
independent	  variable.	  
Of	  the	  initial	  cohort	  of	  62	  patients	  with	  serial	  muscle	  ultrasounds,	  8	  had	  incomplete	  
or	  missing	  electronic	  scan	  records.	  Of	  the	  remaining	  54,	  11	  had	  >1	  scan	  where	  the	  
femur	   was	   not	   visualized.	   Two	   assessors	   analysed	   images	   at	   21	   time-­‐points	   to	  
establish	   inter-­‐rater	   reliability.	   Thickness	   measurements	   were	   highly	   correlated	  
between	  observers	   (AM	  and	   ZP:	   Pearson	   r=0.98)	  with	   an	   intra-­‐class	   co-­‐efficient	   of	  
0.986	   (95%CI	   0.965-­‐0.994).	   	   A	   Bland	   Altman	   plot	   demonstrated	  minimal	   bias	   of	   	   -­‐
0.07±0.2	  cm	  (95%CI	  -­‐0.46-­‐0.32	  cm).	  
Nineteen	  patients	  had	  Thickness,	  RFCSA,	  fibreCSA	  and	  protein/DNA	  ratio	  measured	  on	  
Day	  1	  and	  Day	  7.	  ΔThickness	  significantly	  underestimated	  ΔfibreCSA	   (-­‐4.6%	  (95%CI	   -­‐
14.19-­‐4.95)	   vs.	   -­‐16.4%	   (95%CI	   -­‐32.0—0.74);	   p=0.025)	   and	   change	   in	   protein/DNA	  
ratio	  ((-­‐4.6%	  (95%CI	  -­‐14.19-­‐4.95)	  vs.	  -­‐30.9%	  (95%CI	  -­‐51.2—10.6);	  p=0.019).	  We	  have	  
previously	   shown	   ΔRFCSA	   	   	   to	   underestimate	   change	   in	   protein/DNA	   ratio	   (10.3%	  
(95%CI	   6.1-­‐14.5)	   vs.	   29.5%	   (95%CI	   13.4-­‐45.6%;p=0.03)	   	   but	   not	   ΔfibreCSA	   (10.3%	  
(95%CI	  6.1-­‐14.5)	  vs.	  17.5%	  (95%CI	  5.8-­‐29.3);p=0.31)	  (8).	  
ΔThickness	  and	  ΔRFCSA	  correlated	  (r2=0.22,	  p=0.049)	  but	  a	  Bland	  Altman	  comparison	  
between	  ΔThickness	  and	  ΔRFCSA	  over	  10	  days	  revealed	  a	  bias	  of	  -­‐8.3%	  ±	  19.7%	  (95%	  
CI-­‐46.7-­‐30.7)	  for	  Thickness	  resulting	  in	  significant	  underestimation	  of	  muscle	  wasting	  at	  
days	  7	  and	  10	  (Figure	  1A	  and	  table	  1).	  
Of	   the	   63	   patients,	   40	   were	   able	   to	   obey	   commands	   and	   underwent	   volitional	  
strength	  testing	  on	  Day	  10,	  amongst	  whom	  Thickness	  was	  available	  in	  27.	  	  
ΔRFCSA	  was	  greater	  in	  those	  with	  knee	  extensor	  weakness	  than	  those	  without	  (20.7%	  
(95CI%	   13.7-­‐27.7)	   vs.	   8.4%	   (95%CI	   2.5-­‐14.3)	   respectively	   p=0.012).	   ΔThickness	   did	  
not	  differ	  between	  these	  groups	   (12.6%	  (95%CI	  0.94-­‐24.2)	  vs.	  12.1	   (95%CI2.7-­‐21.5)	  
respectively,	   p=0.95)	   (Figure	   1B).	   In	   a	   bivariable	   logistical	   regression,	   ΔRFCSA	   was	  
associated	  with	   knee	  extensor	  weakness	   (OR	  1.101	   (95%CI	  1.011-­‐1.199);	   p=0.027),	  
but	  ΔThickness	  was	  not	  (OR	  1.001	  (95%CI	  0.960-­‐1.044);	  p=0.947).	  	  
All	  other	   things	  being	  equal,	  muscle	   strength	  and	  size	  are	  proportional	   -­‐	   the	   latter	  
acting	  as	  a	  proxy	  for	  the	  former	  in	  ICU,	  where	  non-­‐volitional	  objective	  measures	  of	  
strength	   are	   logistically	   challenging.	   	   Our	   results	   suggest	   that	   ΔRFCSA	   reflects	   knee	  
extensor	   weakness	   and	   muscle	   loss	   better	   than	   ΔThickness.	   ΔThickness	   also	  
underestimated	  ΔRFCSA	  	  (a	  -­‐8%	  bias	  on	  Bland	  Altman	  plot	  being	  relevant,	  given	  that	  a	  
10%	  change	  in	  RFCSA	  is	  considered	  sufficient	  to	  affect	  function(11))-­‐	  in	  part,	  perhaps,	  
because	  it	  is	  a	  unidimensional	  measure	  when	  compared	  to	  (2D)	  muscle	  area	  or	  (3D)	  
volume.	  The	   specific	   relationship	  of	   tissue	  edema	   to	  ultrasound	  measures	   remains	  
unclear	  (3,	  8),	  though	  edema	  may	  also	  affect	  FibreCSA	  (12).	  
Although	   these	   data	   are	   derived	   from	   the	   largest	   cohort	   available	   for	   longitudinal	  
radiopathological	   correlation,	   our	   study	   is	   limited	   by	   its	   size.	   	   The	   cohort	   size	  was	  
further	   limited	  by	  a	   third	  of	  patients	  not	  being	  able	   to	  perform	  volitional	   strength	  
testing,	  albeit	  this	  being	  in	  keeping	  with	  published	  rates	  (13).	  Finally,	  measurement	  
of	  Thickness	  was	  not	  an	  original	  primary	  goal	  of	   image	  analysis,	  a	  fact	  which	  might	  
account	  for	  the	  lack	  of	  femoral	   image	  availability	  in	  one	  third.	  Although	  considered	  
unlikely	   to	   have	   impacted	   on	   the	   observations	  made,	   non-­‐random	  bias	   cannot	   be	  
excluded.	  
We	   have	   previously	   shown	   RFCSA	   studies	   to	   indicate	  muscle	   quality	   (3)	   and	   not	   to	  
underestimate	   muscle	   fibreCSA.	   We	   now	   show	   that	   Thickness	   measurements	  
significantly	  underestimate	  ICU	  muscle	  wasting	  compared	  to	  RFCSA.	  In	  addition	  RFCSA	  
is	  a	  more	   reliable	  proxy	   for	  muscle	   strength	   in	  a	   setting	  where	  volitional	  and	  non-­‐
volitional	  muscle	  strength	  measurements	  are	  challenging.	  We	  suggest	  measurement	  
of	   ΔRFCSA	   as	   a	   biomarker	   for	   proximal	   lower	   limb	   muscle	   loss	   and	   knee	   extensor	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Figure	   1AB:	   (A)	   Change	   in	   Rectus	   Femoris	   Cross	   Section	  Area	   (RFCSA)	   and	  Muscle	  
Layer	  Thickness	  (Thickness)	  over	  10	  days	  of	  critical	  illness.	  *	  Represents	  p<0.05	  and	  
**	   p<0.01	   using	   Two-­‐way	   repeated	  measures	   Analysis	   of	   Variance	   (ANOVA).	   (B)	  
Knee	  Extensor	  Medical	  Research	  Council	  (MRC)	  	  Strength	  Score	  and	  loss	  of	  muscle	  
size	  as	  measured	  by	  Rectus	  Femoris	  Cross	  Sectional	  Area	  (RFCSA)	  and	  Muscle	  Layer	  




	   ΔTHICKNESS	   ΔRFCSA	   	  
Day	  7	   -­‐5.88%	  (-­‐11.69—0.06%)	   -­‐13.0%(-­‐16.52—9.48%)	   0.031*	  
Day	  10	   -­‐9.36%	  (-­‐15.43—3.84%)	   -­‐17.72	  (-­‐21.15—14.29)	   0.004*	  
Table	  1:	  Comparison	  of	  change	  in	  Muscle	  Limb	  Thickness	  (ΔTHICKNESS)	  and	  Rectus	  Femoris	  Cross	  Sectional	  
Area	  (ΔRFCSA)	  at	  days	  7	  and	  10	  of	  critical	  illness.	  *Represents	  p<0.05	  using	  2-­‐way	  repeated	  measures	  Analysis	  
of	  Variance	  (ANOVA).	  
	  
	  
